John Heymach
MD, PhD
Chair, Department of Thoracic/Head and Neck Medical Oncology
👥Biography 个人简介
John Heymach has led the clinical development of poziotinib for EGFR and HER2 exon 20 insertion mutations. His translational research program at MD Anderson integrates structural biology with drug design for uncommon EGFR variants. He has pioneered combination strategies to overcome resistance in exon 20 mutant tumors.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 John Heymach 的研究动态
Follow John Heymach's research updates
留下邮箱，当我们发布与 John Heymach（MD Anderson Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment